Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Merrimack Pharmaceuticals, Inc.

Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Tickers MACK
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Tickers MACK
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Tickers MACK
Merrimack Receives $225 Million Milestone Payment from Ipsen
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Tickers MACK
Merrimack Reports Full Year 2023 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Tickers MACK
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Tickers MACK
Merrimack Reports Third Quarter 2023 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Tickers MACK
Merrimack Reports Second Quarter 2023 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Tickers MACK
Merrimack Reports First Quarter 2023 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Tickers MACK
Merrimack Reports Full Year 2022 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Tickers MACK
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Tickers MACK
Merrimack Provides Ipsen Report That Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Merrimack Reports Third Quarter 2022 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Tickers MACK
Merrimack Reports Second Quarter 2022 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Tickers MACK
Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Tickers MACK
Merrimack Reports First Quarter 2022 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Tickers MACK
Merrimack Reports Third Quarter 2021 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Tickers MACK
Merrimack Reports Second Quarter 2021 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Tickers MACK
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.